Oligonucleotide Therapeutics and Delivery Conference 2022

Memo

Advancements in extra-hepatic delivery of oligonucleotidesThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.Benefits of attending:- Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials- Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity- Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development- Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA- Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeuticsPlus, two interactive half day pre-conference workshops on 20th September 2022:- Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development and Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge- Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC ConsultingCHAIRS FOR 2022:- Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon- Jimmy Weterings, Principal Scientist, AstraZeneca FEATURED 2022 SPEAKERS INCLUDE: - Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca- Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech - Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals- Sarah Tabrizi, Director of UCL Huntington's disease centre, UCL Institute of Neurology- Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets- David Evans, Chief Scientific Officer, Sirnaomics- Eric Lim, Director, Platform, Discover Research, Stoke Therapeutics, Inc.- Chris Chorley, Associate Director, Global Regulatory CMC, Biogen - Oliver Ernst, Managing Director, Chief Operating Officer, Neuway Pharma GmbH- Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator- Bart Anderson, Senior Director of R and D, ExicureWho should attend:- Executives, Directors, VPs, Heads, Principals, Managers of:- RNA Biology/Discovery- Novel Therapeutic Modalities- Innovation Technologies- C-level Scientific Executives- Formulation and Drug Delivery- Clinical Research and Development- Cell BiologyEARLY-BIRD RATES:- BOOK BY 29TH APRIL AND SAVE £400- BOOK BY 31ST MAY AND SAVE £300- BOOK BY 30TH JUNE AND SAVE £200 Additional Contact Info:T: +44 (0)20 7827 6154E: This email address is being protected from spambots. You need JavaScript enabled to view it. LinkedIn: SMi PharmaTwitter: @SMiPharma | #SMiOligonucleotides   Date and Time: On Wed, 21 Sep 2022 at 9:00 AM - Thu, 22 Sep 2022 at 5:00 PM Venue details: Copthorne Tara Hotel London Kensington, Scarsdale Pl, London, England, W8 5SY, United Kingdom Price:General Admission: GBP 1499.00